Author:
Yamato Masaya,Kinoshita Masahiro,Miyazawa Shogo,Seki Masayuki,Mizuno Tomoki,Sonoyama Takuhiro
Abstract
ABSTRACTIntroductionAntivirals with differing mechanisms of action are needed for COVID-19 treatment; remdesivir is mainly used in hospitalized patients, but additional antivirals are needed in this setting. Ensitrelvir, a 3C-like protease inhibitor, received emergency approval in Japan in November 2022, based on evidence of rapid symptom resolution in non-hospitalized patients, but confirmation of its efficacy in hospitalized patients is lacking.Case presentationsThis case series reports outcomes for all patients who received ensitrelvir whilst hospitalized with SARS-CoV-2 infection at Rinku General Medical Center, Japan (November 2022– April 2023). Thirty-two hospitalized patients received five days of ensitrelvir treatment (375/125 mg). Mean age was 73.5 years and most patients had mild COVID-19. Patients exhibited various underlying diseases, most commonly hypertension (78.1%) and chronic kidney disease (25.0%). Seven (21.9%) patients were on hemodialysis. The most common concomitant medications were antihypertensives (59.4%) and corticosteroids (31.2%); two (6.3%) patients were being treated with rituximab; 27 (84.4%) patients had viral persistence following pre-treatment remdesivir failure. Following ensitrelvir treatment, all patients experienced clinical improvement as assessed by the investigator. No ICU admissions or deaths due to COVID-19 occurred. Viral clearance was recorded in 18 (56.3%) patients by day 5 and 25 (78.1%) patients at final measurement. No new safety signals were observed.DiscussionThis case series represents ensitrelvir clinical efficacy in hospitalized patients with SARS-CoV-2 in a real-world setting. Most patients experienced persistent viral shedding despite pre-treatment with antivirals, and most were considered high-risk due to underlying conditions. Despite this, no patients experienced progression of COVID-19 to severe or critical disease, including those who failed prior remdesivir treatment. The antiviral activity of ensitrelvir demonstrated here indicates it is a viable treatment option for SARS-CoV-2 infection in this setting.ConclusionEnsitrelvir was associated with potent antiviral activity and positive clinical outcomes in high-risk, hospitalized patients with various comorbidities.Trial RegistrationUMIN000051300Key Summary PointsWhy carry out this study?Real-world evidence of ensitrelvir for the treatment of COVID-19, especially in inpatient settings, is required.This was a retrospective cohort analysis, consisting of 32 high-risk hospitalized patients with a range of disease severities and comorbidities, including patients who had experienced remdesivir treatment failure.What was learned from the study?All patients experienced clinical improvement following ensitrelvir treatment, without any worsening COVID-19.Viral clearance was documented in 78.1% of patients at final viral measurement.No new safety signals of ensitrelvir were observed in this analysis.
Publisher
Cold Spring Harbor Laboratory
Reference61 articles.
1. The COVID-19 Pandemic: A Comprehensive Review of Taxonomy, Genetics, Epidemiology, Diagnosis, Treatment, and Control
2. WHO. WHO Director-General’s opening remarks at the media briefing on COVID-19-11 March 2020. https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19 11-march-2020. Accessed Aug 9 2023.
3. WHO. WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int/. Accessed Aug 9, 2023.
4. WHO. One year since the emergence of COVID-19 virus variant Omicron. https://www.who.int/news-room/feature-stories/detail/one-year-since-the-emergence-of-omicron#:~:text=It%20was%2026%20November%202021,of%20the%20COVID%2D19%20pandemic. Accessed Aug 9, 2023.
5. SARS-CoV-2 Omicron variant: recent progress and future perspectives
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Antiviral therapy for COVID-19;COVID-19: An Update;2024-09-01